Raptor Pharmaceutical Corp. (NASDAQ: RPTP) is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare debilitating and often fatal diseases.
Raptor's first product, PROCYSBI® (cysteamine bitartrate) delayed-release capsules, received FDA approval in April 2013 for the management of nephropathic cystinosis in adults and children 6 years and older. In Europe, PROCYSBI® gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate) received European Commission approval in September 2013 for the treatment of proven nephropathic cystinosis.
The company has active clinical development programs in multiple therapeutic areas such as nephropathic cystinosis, nonalcoholic fatty liver disease, Huntington's disease (HD), and Leigh syndrome and other mitochondrial disease. Raptor holds several orphan drug designations, including U.S. orphan drug designation for RP103 in Huntington's disease. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson’s disease, Rett Syndrome and the treatment of MeCP2-associated disorders. For additional information, please visit www.raptorpharma.com.
Raptor’s management team consists of repeat entrepreneurs with the experience to build a successful company.
To learn more about Raptor Pharmaceuticals, please review our corporate presentation.